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Abstract
Background: Dementia is very common in Down syndrome (trisomy 21) adults. Statins may slow brain amyloid β
(Aβ, coded on chromosome 21) deposition and, therefore, delay Alzheimer disease onset. One prospective cohort
study with Down syndrome adults found participants on statins had reduced risk of incident dementia, but there
are no randomised controlled trials (RCTs) on this issue. Evidence is sparse on the best instruments to detect
longitudinal cognitive decline in older Down syndrome adults.
Methods: TOP-COG was a feasibility/pilot, double-blind RCT of 12 months simvastatin 40 mg versus placebo for the
primary prevention of dementia in Alzheimer disease in Down syndrome adults aged 50 years or older. Group
allocation was stratified by age, apolipoprotein E (APOE) ε4 allele status, and cholesterol level. Recruitment was from
multiple general community sources over 12 months. Adults with dementia, or simvastatin contraindications, were
excluded. Main outcomes were recruitment and retention rates. Cognitive decline was measured with a battery of
tests; secondary measures were adaptive behaviour skills, general health, and quality of life. Assessments
were conducted pre randomisation and at 12 months post randomisation. Blood Aβ40/Aβ42 levels were
investigated as a putative biomarker. Results were analysed on an intention-to-treat basis. A qualitative
sub-study was conducted and analysed using the Framework Approach to determine recruitment
motivators/barriers, and participation experience.
Results: We identified 181 (78 %) of the likely eligible Down syndrome population, and recruited 21
(11.6 %), from an area with a general population size of 3,135,974. Recruitment was highly labour-intensive.
Thirteen (62 %) participants completed the full year. Results favoured the simvastatin group. The most
appropriate cognitive instrument (regarding ease of completion and detecting change over time) was the
Memory for Objects test from the Neuropsychological Assessment of Dementia in Individuals with
Intellectual Disabilities battery. Cognitive testing appeared more sensitive than proxy-rated adaptive
behaviour, quality of life, or general health scores. Aβ40 levels changed less for the simvastatin group (not
statistically significant). People mostly declined to participate because of not wanting to take medication,
and not knowing if they would receive simvastatin or placebo. Participants reported enjoying taking part.
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Conclusion: A full-scale RCT is feasible. It will need 37 % UK population coverage to recruit the required 160
participants. Information/education about the importance of RCT participation is needed for this population.
Trial registration: ISRCTN67338640.
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Background
Adults with Down syndrome have a very high prevalence
of dementia of an Alzheimer disease type; indeed Down
syndrome is the commonest cause of early-onset demen-
tia, with 40 % of those aged 50 and over having acquired
it [1, 2]. There are no preventative measures routinely
available, and hence it is an exceedingly high priority to
identify effective interventions.
The amyloid precursor protein (APP) gene is over-
expressed in Down syndrome (trisomy 21) as it is
located on chromosome 21. This leads to amyloid β
(Aβ) overproduction, which is thought to be the under-
lying cause of the high rates of Alzheimer disease [3].
Unlike the general population, adults with Down
syndrome develop a relatively ‘pure’ amyloid form of
Alzheimer disease, as they have a remarkable resilience
to atherosclerosis, being atheroma-free, with low blood
pressure, and having low vascular dementia rates [4, 5].
This may be because the cystathionine β synthase (CBS)
gene is also located on chromosome 21, and so is over-
expressed. This results in trans-sulphuration of homo-
cysteine to cysteine, and a lower than normal plasma
homocysteine level (the opposite of homocysteinuria,
which can be due to CBS deficiency, resulting in hyper-
homocysteinaemia and early and aggressive arterial dis-
ease). This means that findings produced by trials in the
general population cannot be assumed to be generalisable
to people with Down syndrome.
Statins (microsomal 3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors) are plausible agents to re-
duce the risk of Alzheimer disease. They have pleiotropic
effects including potentially increasing brain amyloid
clearance by the low-density lipoprotein receptor (LDLR)
family of proteins. Experimental animal models support
this [6, 7]. Foetal brain LDLR activity has been shown
in vitro to be increased significantly, especially in astro-
cytes, by statin treatment [8].
In humans, there has been little study of statins in
adults with Down syndrome. In the single observational
Down syndrome study that we could identify, statin use
and incident dementia was prospectively investigated
over a 5-year period in 123 participants aged 40 years
and older [9]. The participants on statins were found to
have less than half the risk of incident dementia, and
persons with Aβ42 in the middle or highest range were
more than twice as likely to have incident dementia [10].
We have identified no randomised controlled trials
(RCTs) of statins in people with Down syndrome.
Regarding the general population, Alzheimer disease is
less prevalent in populations with low blood cholesterol
and diets that are low in fat and cholesterol [11, 12].
Several case-control studies have reported a lower risk
of dementia among statin users [13–19]. Prospective
cohort studies have found that statins predicted
reduced incidence of dementia or slower cognitive
decline [19–26], or reduced hospitalisation due to de-
mentia [27]. Other studies reported no associations of
statin use with Alzheimer disease [18, 28, 29], but did
not distinguish Alzheimer disease from the vascular
dementias, or had unusually high baseline educational
levels. A further complication is whether the observed
period of statin exposure was during the at-risk period.
A recently updated Cochrane review found only two
published statin RCTs for the primary prevention of
dementia in the general population [20]: the MRC/BHF
Heart Protection Study (HPS) [30] and the Prospective
Study of Pravastatin in the Elderly at Risk (PROSPER)
study [31]. Neither reported benefits. However, their study
participants were selected specifically for having vascular
disease and/or vascular risk factors, so are not directly
relevant to adults with Down syndrome who have Aβ
overproduction. Pravastatin, used in PROSPER, acts on
vascular targets but not any within the central nervous
system as it is hydrophillic; hence, theoretically it is
unlikely to be effective in preventing dementia in people
with Down syndrome. Conversely, simvastatin is lipophilic
and crosses the blood-brain barrier. Smaller studies in-
cluding ‘Alzheimer disease high-risk groups’ have found
benefits at 4 months and 6 months [32, 33], although not
consistently so [34]. A small, secondary prevention RCT
showed promising results of atorvastatin in slowing cogni-
tive decline at 6 and 12 months [35], whereas two larger
RCTs did not [36, 37]. However, theoretically, statins may
be more effective in primary than in secondary prevention.
Authors of two more reviews concluded that trials are
indicated specifically when Alzheimer disease is due to
amyloid overproduction [38, 39], and a recent systematic
review concluded that there is an absence of well-powered
RCTs for most cognitive outcomes of statins and that lar-
ger and better-designed studies are needed [40]. However,
this general population literature is unlikely to be relevant
to the atheroma-free Down syndrome population.
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Adults with Down syndrome have pre-existing cognitive
deficits and, therefore, existing norms on neuropsycho-
logical test instruments designed for the general popula-
tion do not apply for them, and these instruments are also
typically too complicated for adults with Down syndrome
to complete, resulting in a ‘floor effect’. There have been
previous studies which measured changes with age using
adapted or specially devised assessment tools [2, 41, 42],
but most are limited by small sample sizes and are
not longitudinal. Measures of cognitive function may
be a more accurate and sensitive measure of decline
than caregiver-reported changes in adaptive function,
particularly given staff-turnover amongst paid carers,
meaning that different carers report at different times
and may not know the person well. Hence, further
delineation of which cognitive tests are most sensitive
is important.
Further details on the background to this study have
been previously reported in a protocol paper [43].
Study aims
The study aims were to:
1. Acquire data to design a full-scale, multi-centre
RCT of simvastatin for the primary prevention of
dementia in Alzheimer disease in older adults with
Down syndrome
2. Test recruitment and retention strategies to inform
future trials with this population
3. Determine the best instruments to use in future
studies measuring cognitive decline in adults with
Down syndrome
4. Investigate mechanisms, using Aβ42/Aβ40
measurements as a putative surrogate biological marker
Research questions
The research questions were to identify:
1. Trial recruitment/retention rates and recruitment
sources
2. Rates of tolerability/safety of simvastatin 40 mg
at night
3. The most sensitive instruments to detect early
cognitive decline with least floor effect with Down
syndrome adults
4. The perceptions of adults with Down syndrome
and their carers on deciding whether to
participate, and to be randomised, and their
experience of the assessments
5. The distributions of the primary (cognitive decline)
and key secondary (adaptive behaviour, general
health, quality of life) outcome measures that would
be used in a definitive RCT, and the sample size
implications of these distributions
6. Whether Aβ42/Aβ40 is a biomarker for
cognitive decline
7. Whether the results support proceeding to a full RCT
Methods
Study methods have previously been reported in more
detail in the protocol paper [43]. A Consolidated
Standards of Reporting Trials (CONSORT) checklist
is provided at Additional file 1.
Study design
TOP-Cog was a feasibility and pilot double-blind RCT
of 12 months simvastatin versus placebo for the primary
prevention of dementia. It included a qualitative study,
analysed using the Framework Approach [44], to de-
termine motivators and barriers to recruitment and
the experience of study participation. We made no
methodological changes after registration.
Setting
The setting was the general community of Scotland, UK,
specifically the health board areas of Greater Glasgow
and Clyde, Lothian, Tayside, Lanarkshire and Borders.
Recruitment was from multiple sources within the general
community, Down Syndrome Scotland, Local Authorities,
and National Health Service clinical services.
Participants
Inclusion criteria
1. Down syndrome
2. Aged 50 years and over
Exclusion criteria
1. No consent obtained
2. Unable to comply with the protocol, including
providing blood or saliva for baseline apolipoprotein
E (APOE) ε4 measurement, and venous or capillary
blood for cholesterol measurement
3. Dementia at baseline (as the study is investigating
primary prevention)
4. Diabetes (as this is an indication for a statin
prescription)
5. Clinically evident atherosclerotic disease (as this is
an indication for a statin prescription)
6. Being at risk for cardiovascular disease (as this is an
indication for a statin prescription)
7. Liver disease
8. Chronic renal insufficiency
9. Being prescribed a statin or medicines that are
listed as contraindicated with simvastatin in its
summary of product characteristics, plus
miconazole oral gel
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10.Having previously had a statin-related serious
adverse event
11.Unable or unwilling to avoid consumption of
grapefruit juice
12.Alcohol use of over 21 units/week for men, or over
14 units/week for women
Intervention and comparison
The intervention was one over-encapsulated simvastatin
40 mg tablet at night for 12 months, compared with one
capsule of placebo at night for 12 months. Tablet and pla-
cebo were identical in appearance and similar in weight.
Outcome measures
Primary measures
1. Recruitment and retention:
(a)Numbers screened and recruited each month
(b)The proportion of participants retained
12 months after randomisation
(c)The number of participants recruited per base
general population size
Secondary measures
1. Adverse and serious adverse events
2. Cognitive test battery to measure cognitive decline:
(a)Memory for Objects from the
Neuropsychological Assessment of Dementia in
Individuals with Intellectual Disabilities
(NADIID) battery [41]
(b)Selective Attention Cancellation Test [42]
(c)Pattern recognition memory from the Cambridge
Neuropsychological Test Automated Battery
(CANTAB) [45]
(d)Cats and Dogs test [46]
(e)Tower of London Test (a test of frontal lobe
executive functioning, recently adapted by our
group for intellectually disabled adults) [47]
(f ) Cued Recall Test [48]
(g)Category Fluency Test (asking participants to
think of as many animals as they can in 1 minute)
(h)Story Recall Test (adapted from the Rivermead
Behavioural Memory Test for Children) [49]
Further information on the cognitive test battery is in-
cluded at Additional file 2.
3. Key themes from semi-structured interviews
4. Estimate of the sample size needed for a full
RCT from the cognitive test battery; EuroQol
5-Dimension Questionnaire (EQ-5D) score,
recently reviewed for the intellectually disabled
population [50]; Townsend Scale score [51];
Adaptive Behaviour Scale – Residential and
Community score (ABS) [52]
5. Aβ40/Aβ42 levels
6. The size of the geographical recruiting area and
hence the likely associated costs of a full trial,
and the sensitivity of, and floor effect on, the
cognitive measures
Group allocation and blinding
Participants were randomly assigned to either simvastatin
or placebo, stratified by age (50–54 years or 55 years and
over), apolipoprotein E (APOE) ε4 allele status (presence
of an ε4 allele or not), and cholesterol level (below
5 mmol/l or 5 mmol/l and over). These stratifications
were made in case of a differential effect on outcome; the
absolute level taken to define high and low cholesterol is
of course an arbitrary decision; as is the absolute age level
to delineate younger and older participants. Regarding
age, we aimed to balance the increased incidence of
dementia with age against the smaller pool of potential
recruits. Since we did not know a priori what the effect
sizes we might detect were, difficulty in recruitment, attri-
tion, etc. at different ages, we predefined an age stratifica-
tion at what we estimated would be the mid-point of the
range of those recruited. To ensure blinding to both
APOE status and group allocation, the researcher notified
the Robertson Centre for Biostatistics (RCB) of the partici-
pant’s study number and age via a web portal. The labora-
tory then notified the RCB of the participant’s APOE
status and cholesterol level via the portal. The RBC then
notified pharmacy of group allocation, and generated an
email to the researcher notifying that randomisation has
taken place, and the medication pack number assigned.
Pharmacy then dispensed the medication by posting it to
participants on a 3-monthly basis from a central pharmacy
(rather than expecting participants/carers to collect it).
Process and assessments
Invitations were distributed to potential participants
from a variety of sources. An initial telephone call was
made to individuals who replied to an invitation, to
discuss study participation. Interested individuals were
then screened for inclusion/exclusion criteria and a
researcher took consent from the person or, for people
who did not have decision-making capacity to consent
for themselves, consent was taken from their legal repre-
sentative, in keeping with the Medicines for Human Use
(Clinical Trials) Regulations, 2004. At the initial home
visit, baseline data were collected on cognitive function,
adaptive function, health, and quality of life. Also taken
at baseline were venous or capillary blood samples for
APOE and cholesterol levels, liver function tests, cre-
atine kinase and thyroid function tests, and if possible,
venous blood for baseline measures of Aβ40/Aβ42.
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Sensory assessments were also conducted to check the
extent to which they could use some of the cognitive
test instruments. Participants were then randomised
and drug/placebo prescribed. After 6–12 weeks a
safety visit was conducted, and blood was taken for
alanine transaminase, aspartate transferase, and creat-
ine kinase. Each participant/carer was then telephoned
at 3, 6 and 9 months to enquire specifically about
adverse events and any changes to supports. Twelve
months after randomisation, cognitive assessments
were repeated at a home visit, as was assessment of
adaptive function, health, quality of life, service use,
and adverse events. Additionally, at 12 months, blood
was taken for cholesterol, liver function tests and
thyroid function tests, and if possible, venous blood
for Aβ40/Aβ42. All biochemical analyses were conducted
in a core Clinical Pathology Accredited laboratory. Serum
was stored frozen at −80 °C. Baseline and 12-month
samples were analysed in the same assay.
For the nested qualitative study, home visits were
undertaken by the researcher 6 months after recruitment
started. Attempts were also made to interview persons
who declined to participate in the RCT. Interviews were
jointly with the person with Down syndrome and their
carer, reflecting the likely way that decisions were taken
about participation in the study. Topic guides were used,
but planned to be flexible because interviews with people
with intellectual disabilities are sometimes challenging
and the interviewer must be patient and sensitive to
the person’s needs. Interviews were tape recorded and
transcribed verbatim.
Power calculation
Recruitment feasibility was planned to be assessed by
the number of people identified/1,000,000, the percent-
ages of those contacted who would like to participate,
and of those, the percentage who were eligible. For
example, if 200 individuals were contacted, and 100
agree to be screened, of whom 60 were eligible for
randomisation, then the overall recruitment rate would
be 30 % with a 90 % confidence interval (CI) of 25–36 %;
sufficiently accurate to allow planning for a larger RCT.
Similarly, if 50 of the 60 participants completed the
12 month follow-up, the retention rate would be 83 %
with a 90 % CI of 73–91 %.
The variance of the rate of cognitive decline was
planned to be estimated to calculate the sample size
required for a definitive RCT; the precision of this esti-
mate is a function of the sample size in this pilot study.
We decided that 50 participants providing 12-month
outcome data was an appropriate sample size to provide
a variance estimate that is reasonably precise, without
recruiting an excessively large sample. With 50 subjects,
a 90 % CI for the variance would have a width of
approximately 70 % of the estimated variance. A smaller
sample size would increase the uncertainty in the vari-
ance estimate, whereas to obtain a more precise estimate
could require considerably more participants, e.g. to half
the width of the 90 % CI for the variance would require
180 subjects, which would have been too large for a pilot
designed to show feasibility of an RCT.
For the qualitative study, we did not know in advance
how many interviews would be necessary to reach satur-
ation, but planned to interview 10 dyads of participants
with Down syndrome/their carer, and attempted to also
recruit 10 dyads of adults with Down syndrome/their
carer who chose not to participate in the pilot RCT.
Sampling was purposive to include both paid carers and
family carers, and people with Down syndrome with a
range of ability levels.
Types of analyses
Results were analysed on an intention-to-treat basis.
Continuous variables are summarised as mean and
standard deviation; categorical variables as frequencies
and percentages. Outcome variables are summarised
at baseline, at 12 months follow-up, and as the change
over time (follow-up minus baseline). For each outcome, a
linear regression model was fitted to estimate the treat-
ment effect (simvastatin minus placebo), where the out-
come variable was the follow-up measurement, and the
predictor variables were randomised treatment group,
the baseline value of the outcome measure, and the
variables used to stratify the randomisation, namely
age (50–54 years or 55 years and over), APOE ε4
allele (presence of an ε4 allele or not), and cholesterol
level (below 5 mmol/l or 5 mmol/l and over). Where
the linear model was a poor fit to the data, outcomes
were collapsed to binary, and binary logistic regres-
sion was used. The estimated treatment effect and
90 % confidence limits were divided by the standard
deviation of the outcome at baseline in the whole
population, giving an estimated effect size and 90 % CI for
each outcome where a linear model was a reasonable fit to
the data.
All statistical analyses were conducted using SAS soft-
ware v9.3 (SAS Institute, Cary, NC, USA).
The qualitative interviews were analysed using the
Framework Approach to identify similarities and differ-
ences in the data and draw descriptive or explanatory
conclusions around themes. After verbatim transcription
of the interviews, the transcripts were read and reread
by CS and JM to familiarise themselves with the data.
Codes were applied to important phrases separately by
the two researchers and, after meeting to discuss the
codes, they were grouped into categories and summarised.
Several meetings then took place between CS and JM to
interpret the data [44].
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Ethics
The study was approved by the Multi-centre Research
Ethics Committee – Scotland A (11/AL/0200), and the
Medicines and Healthcare Products Regulatory Agency
(EudraCT number 2011-001564-21). NHS research and
development site approvals were gained from NHS
Greater Glasgow and Clyde, Lothian, Tayside, Lanarkshire,
and Borders. Approvals were also required and gained
from Edinburgh Council, and Glasgow City Council.
South Lanarkshire Council refused ethical approval. Other
local authorities did not require ethical submission. The
sponsor’s protocol for assessing and reporting adverse
events in clinical trials of investigative medicinal products
was adhered to.
Results
Trial recruitment/retention rates and recruitment sources
We recruited and randomised 21 participants over a
12-month period.
Scotland’s census, 2011 data reveals the base population
size of the area we recruited from was 3,135,974; including
2,579,698 adults. Hence, we expected there to be 387 adults
with Down syndrome aged 50 years and over [53]. For this
age group, we would expect about 40 % to have dementia
[1, 2], our major exclusion criteria, leaving 232 eligible to
be considered for the trial. We identified 217 adults ini-
tially thought to be eligible, but on further consideration,
36 had dementia, hence we identified 181 potential par-
ticipants; 78 % of the expected eligible population.
We invited the potential participants, and after assessing
inclusion and exclusion criteria, randomised 21 of these
181 individuals (11.6 %). Their characteristics were bal-
anced in the two arms (Table 1). Recruitment, therefore,
was 21 participants from a population size of 3,145,974
(or 6.7/1,000,000 whole population), and by area was:
 9 in Greater Glasgow and Clyde (7.4/1,000,000)
 6 in Lothian (10.8/1,000,000)
 3 in Tayside (7.3/1,000,000)
 2 in Lanarkshire (3.5/1,000,000)
 1 in Borders (8.8/1,000,000)
Figure 1 shows the recruitment flowchart. Figure 2
shows cumulative randomisation over time.
We did not recruit any participants via organisations
providing support for people with learning disabilities,
despite attempting to. Recruitment sources were:
 Scottish Primary Care Research Network – 5 (Fig. 3)
 Learning disabilities day centres – 4 (Fig. 4)
 Learning disabilities psychiatrists – 4
 Other learning disabilities health professionals – 3
 Previous participants of the chief investigator’s
research – 3
 Down Syndrome Scotland – 2
Twenty additional individuals responded to the invita-
tion expressing interest to participate, but were ex-
cluded. They were identified via:
 Scottish Primary Care Research Network – 5
 Learning disabilities day centres – 3
 Learning disabilities health professionals – 1
 Previous participants of the chief investigator’s
research – 10
 Down Syndrome Scotland – 1
Thirteen (61.9 %) of the 21 participants completed the
trial in full. Table 2 reports the reasons why eight partici-
pants did not complete the 12 months of medication; three
of these eight completed the 12-month post-randomisation
interview. Hence, the 12-month interviews were completed
by seven (70 %) in the simvastatin group and nine (82 %) in
the control group. A CONSORT flow diagram is included
in Additional file 3.
By extrapolation, to recruit 160 into a full-scale RCT, to
retain 99, a population size of approximately 23.9 million
is required.
Tolerability/safety
There were no serious adverse events, and no adverse
events definitely attributable to medication.
Most sensitive instruments to early cognitive decline with
least floor effect
Table 3 shows how many participants were able to
complete the cognitive tests. Table 4 shows the distribution
Table 1 Baseline demographics
Characteristic Overall N = 21 Control N = 11 Intervention N = 10
Age (years)
Mean (SD) 54.15 (3.10) 53.67 (3.16) 54.68 (3.10)
Sex
N (%) male 11 (52 %) 6 (55 %) 5 (50 %)
N (%) female 10 (48 %) 5 (45 %) 5 (50 %)
APOE
N (%) ε3/2 2 (10 %) 1 (9 %) 1 (10 %)
N (%) ε3/3 13 (62 %) 7 (64 %) 6 (60 %)
N (%) ε4/3 6 (29 %) 3 (27 %) 3 (30 %)
Ability
N (%) mild ID 4 (36 %) 4 (36 %) 0 (0 %)
N (%) moderate ID 7 (33 %) 3 (27 %) 4 (40 %)
N (%) severe ID 9 (43 %) 4 (36 %) 5 (50 %)
N (%) profound ID 1 (5 %) 0 (0 %) 1 (10 %)
APOE apolipoprotein E gene, ID intellectual disability
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(mean and standard deviation) for outcome measures at
baseline, 12 months, and change over time, as well as treat-
ment effect estimates expressed as effect sizes with 90 %
CIs. Effect size estimates have been reversed where neces-
sary, so that a positive effect can be viewed as a benefit for
the simvastatin group.
The tests that most people could complete, and
which showed decline over time without floor effect,
were the number of objects correct in the NADIID
Memory for Objects test [41], the Category Fluency
Test, and the Cued Recall Test [48]. The Tower of
London Test (revised for this population) [47] was
also off the floor, being completed by all but one
person, but showed less change. The Selective Attention
Cancellation Test [42] showed some utility. These tests
represent a mix of memory, executive function, and atten-
tion tests and together appear the most appropriate
primary and secondary cognitive outcome measures for a
full-scale RCT.
The Cats and Dogs test [46], Story Recall Test [49],
and CANTAB pattern recognition memory test [45] had
poor utility in terms of participant completion.
Perceptions of adults with Down syndrome/carers on
deciding whether to participate, accept randomisation,
and their experience of assessments
Semi-structured interviews were conducted with 10
participant/carer dyads who participated in the RCT,
and four who had declined (consent was subsequently
withdrawn from one). An additional five who had declined
provided written responses to the topic guide, but were
unwilling to be interviewed.
The analysis identified seven main themes; the numbers
in inverted commas reference the supporting quotations
which are provided in Additional file 4.
 Value of research. All RCT participants felt research
to be worthwhile and important ["1, 2"]. They felt it
Fig. 1 Recruitment flowchart
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is a way to increase our understanding and improve
what we already know ["3, 4"]. Those who declined
to participate also acknowledged that research has
value ["5"]. Some who declined felt they did not
know enough about research ["6, 7"].
 Information sheets are useful, and an additional
resource. Most participants felt that the information
sheets were useful and had just enough information
["8–10"]. Additionally, they saw them as an added
resource to draw upon for information on dementia
and Down syndrome ["11, 12"]. All RCT participants,
and those who declined, felt the source of the
information sheets would not have impacted upon
their decision whether or not to participate ["13–16"].
 Preventing the onset of dementia was the primary
motivation for deciding to participate. All
participant/carer dyads expressed concern about
developing dementia ["17–20"]. Preventing the onset
of dementia was the primary motivator in deciding
to participate ["21–23"]. Additionally, some
participants believe that helping others is a reason to
participate ["24, 25"].
 Taking tablets was the most common reason for
declining to participate. All who declined RCT
participation cited taking tablets as the main
reason ["26–28"]. Some expressed concern over
potential side effects ["29, 30"]. Not knowing
whether they would be taking a placebo or statin
was also a participation deterrent ["31, 32"].
 Tablets are acceptable if they are necessary. Overall,
most participant/carer dyads did not have a problem
with taking tablets if they are necessary. A number
were already taking tablets ["33–36"]. Though
sometimes difficult, the majority understood the
need for being blind to placebo or statin ["37–40"] – it
just influenced their decision
 Taking part in the RCT is a positive experience.
Participants enjoyed taking part in the RCT ["41–43"].
Some felt it provided an opportunity to learn new
things about their relative ["44, 45"]. The majority
stated that it was unobtrusive ["46, 47"] and the
assessments interesting ["48"].
 Lack of accessible information on Down syndrome
and dementia. Almost all participants felt they
lacked access to research and information regarding
Down syndrome and dementia ["49–52"]. Many
participants were not told about the risk of
developing dementia ["53, 54"].
Additionally, at the point of declining, 19 people
indicated why:
 Not wanting medication – 6
 Wanting to keep things normal – 3
Fig. 2 Cumulative randomisation over time
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 Too much going on – 3
 Thinking the study was illegal – 2
 Not wanting to ‘go down that road’ – 1
 Carer not wanting to upset relative with Down
syndrome – 1
 Viewing it as disgusting – 1
 Thinking it was too confusing – 1
 Concern about challenging behaviour – 1
Some general practices contacted via the SPCRN de-
clined to participate on the grounds that they had very
few patients who were likely to be eligible.
Distributions of the outcome measures, and sample size
implications
The NADIID Memory for Objects test scores at baseline
and 12 months were on average near the middle of the
possible range (0–10) and showed a difference between
groups, due to an increase in the treatment group and
decrease in the control group (Table 4). The reduced
standard deviation of the change over time compared to
the baseline and 12-month scores indicates a strong cor-
relation over time, suggesting improved efficiency from
an analysis adjusted for baseline scores. The CI for the
effect size estimates with this outcome suggests the true
effect size from simvastatin treatment to be at least 0.4.
Point estimates of the effect sizes for other cognitive
measures were mixed, with some positive (in favour of
simvastatin) and others negative. However, none showed
a statistically significant effect (in either direction) and
all had CIs for the effect size estimate that were consist-
ent with true effect sizes of at least 0.4, with the excep-
tion of the CANTAB pattern memory recognition score,
which had the greatest floor effect. Standard deviation
estimates for the changes over time with other cognitive
measures were of a similar magnitude to individual mea-
sures, suggesting some correlation over time, but less
marked than with the NADIID Memory for Objects test.
Fig. 3 Recruitment via the Scottish Primary Care Research Network
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These data suggest that the NADIID Memory for Ob-
jects test may be the best single measure for future use. A
clinically relevant 1-point difference between groups at
12 months would be an effect size of 0.42, relative to the
standard deviation of scores at baseline, but in relation to
the standard deviation of changes over 12 months, would
be an effect size of 0.67. A study with 48 participants in
each group would be required for 90 % power to detect
such a difference, i.e. 160 participants at baseline with
62 % retention.
The cognitive test battery, as expected, had more utility
than the ABS (proxy-report on skills and function), which
had poor sensitivity to change over the 12 months (Table 5).
Of the 10 ABS domains, the language domain showed
significantly better outcomes for the intervention compared
to the control group (p = 0.0168), but other domains did
not appear sensitive to change over this 1-year period. The
cognitive test battery also showed more utility than the EQ-
5D. The Townsend Scale (general health) better distin-
guished groups than the ABS or EQ-5D (Table 5).
Aβ42/Aβ40
Fourteen people donated blood at both baseline and 12-
month follow-up for analysis of Aβ42/Aβ40. After adjust-
ing for stratification factors, change over the 12 months
was less for the simvastatin group by 24.4 pmol/l for Aβ40
(p = 0.122), by 0.26 pmol/l for Aβ42 (p = 0.868), and by
0.02 for the Aβ42/Aβ40 ratio (p = 0.809).
Fig. 4 Recruitment via learning disabilities day centres
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Do the results support proceeding to a full RCT?
The rationale for proceeding to a full RCT remains.
Based on the cognitive test results, we propose the
NADIID Memory for Objects test as the primary
outcome measure and found no reason not to
proceed to a full-scale RCT. There were no safety
reasons identified for not proceeding to a full-scale
RCT.
The results show that a sample size of 160 is needed
in a full-scale RCT, to retain approximately 100 in the
final analysis at 12 months. This will require recruitment
across a population of 23.9 million, or 37 % of the UK
(population = 64.1 million). We therefore conclude a that
full-scale RCT is feasible in the UK, and affordable given
the potential benefits.
Discussion
This study has provided valuable data essential to design
a much needed full-scale RCT. It is now possible to
design a RCT with a realistic recruitment strategy, and
to seek an appropriate level of funding to implement it.
Even with the general population, recruitment is often
challenging in trials; a study of 114 UK trials funded by
the Medical Research Council (MRC) and National In-
stitute for Health Research - Health Technology Assess-
ment programme (HTA) found that only 31 % recruited
successfully, whilst 45 % recruited less than 80 % of
intended, and more than half required an extension [54].
A recent Cochrane review synthesised the evidence
around strategies to improve recruitment to RCTs [55],
and concluded that trialists should include evaluations
of their recruitment strategies. Studies with people with
learning disabilities are considerably more challenging
than general population studies; indeed they are notori-
ously difficult to recruit into [56–58], and RCTs to
investigate medications are rare with this population
[59]. Hence, this study was essential prior to designing a
full-scale RCT. Additionally, we did not know the propor-
tion of the potentially eligible population we would iden-
tify in order to invite them, and we now have this data.
Most participants were recruited via health profes-
sionals and day services. Time invested in meeting
managers of support-providing organisations did not
translate into recruitment. The study was boosted by
the Scottish Primary Care Research Network adoption,
although labour-intensive for the network as it involved
approaching all practices, rather than the small number of
research-friendly practices that the network usually work
with. This may become less onerous as plans to enable
remote access to general practitioner data for research are
spreading throughout the UK [60]. As some practices
declined to participate because they had few eligible
participants, a full-scale RCT should, in its initial letter to
practices, more prominently highlight that each practice
will have few, and hence the need to recruit through as
many practices as possible.
Whilst there might be recruitment, recruitment source,
and retention variation across the UK, we consider the
study findings highly informative, particularly as they
spanned five health boards, rather than a single service. In
view of possible variability, a full-scale RCT should include
an internal recruitment pilot in several UK sites.
Table 3 Completion of cognitive tests
Test Unable to complete
at baseline N= 21
Unable to complete
at 12 months N= 16
NADIID Memory for
Objects test
1 1
Selective Attention Cancellation
Test – overall score
6 3
CANTAB pattern recognition
test – % correct
10 3
Cats and Dogs switching
condition – time taken
6 5
Cats and Dogs switching
condition – errors
6 5
Tower of London Test
(revised) – total score
1 3
Cued Recall Test – overall score 5 2
Category Fluency Test – total
number of words correct
2 2
Category Fluency Test – total
number of repeated words
2 2
Category Fluency Test – number
of errors
2 2
Story Recall Test – free recall
total score
3 6
Story Recall Test – cued recall
total score
3 6
CANTAB Cambridge Neuropsychological Test Automated Battery, NADIID
Neuropsychological Assessment of Dementia in Individuals with
Intellectual Disabilities
Table 2 Reasons for not completing the full year of medication
Reason Group allocation
Skin rash and GP advised to stop medication Simvastatin
Weight loss, hitting leg – symptoms preceded
taking the medication, but relative thought possibly
worse so stopped medication
Simvastatin
Onset of thyroid dysfunction and carer chose
to stop medication
Placebo
History of episodic diarrhoea. Diarrhoea after
commencing medication so relative
stopped medication
Simvastatin
GP prescribed a statin Placebo
Paid carer withdrew consent Simvastatin
Dementia diagnosed, and relative
stopped medication
Placebo
Participant changed their mind Placebo
Cooper et al. Trials  (2016) 17:370 Page 11 of 16
The nested qualitative study findings largely endorse
our approaches, rather than generating new ideas to
improve recruitment and retention. The main reason
people did not participate was concern about taking the
medication, and not knowing which group they would
be randomised to. The study was about prevention,
rather than treatment, which might have had a bearing,
given that people were taking medication for other
conditions when they needed it. It also seems some
people with Down syndrome and some paid carers are
not aware of the high dementia risk. There are likely to
be other reasons for non-participation, as this informa-
tion only comes from people who were willing to partici-
pate in the qualitative study. It therefore largely provides
information relevant to participation in medication tri-
als, rather than other types of research. In view of this
information, trial participation rate, and other findings,
e.g. failure to gain ethical approval in South Lanarkshire,
we consider that there is a considerable need for publi-
city and education on the reasons for and benefits of
conducting RCTs with this population. Such a ‘campaign’
to engage support providers, service users, relatives, and
Table 5 Mean and standard deviation (SD) for cholesterol, quality of life, and functional scores at baseline, 12 months, and
change over time
Placebo Simvastatin Effect size
Baseline 12 months Change Baseline 12 months Change
Cholesterol 5.3 (0.8) 5.4 (0.7) 0.1 (0.4) 5.1 (0.5) 4.7 (0.7) −0.4 (0.9) 1.5 (−0.8, 3.9)
EQ-5D health utility 0.81 (0.29) 0.75 (0.29) −0.06 (0.20) 0.54 (0.38) 0.68 (0.25) 0.14 (0.38) 0.1 (−0.7, 0.8)
ABS total score 224 (39) 214 (38) −10 (12) 177 (50) 170 (56) −7 (20) −0.1 (−0.4, 0.2)
Townsend Scale total score 8.2 (3.0) 8.1 (3.4) −0.1 (1.3) 9.3 (4.3) 11.3 (3.3) 2.0 (3.4) 0.7 (0.0, 1.4)
Effect size reported as estimated between-group difference, adjusted for baseline score and stratification variables, divided by baseline SD in whole population,
and reversed where necessary so that a positive effect size corresponds to a benefit for simvastatin group
ABS Adaptive Behaviour Scale, EQ-5D EuroQol 5-Dimension Questionnaire
Table 4 Mean and standard deviation (SD) on cognitive tests at baseline, 12 months, and change over time
Placebo Simvastatin Effect size
Baseline 12 months Change Baseline 12 months Change
NADIID
Memory for Objects test 5.7 (2.3) 4.9 (2.6) −0.8 (1.2) 4.0 (2.4) 5.3 (2.7) 1.3 (1.0) 1.0 (0.4, 1.6)
Selective Attention Cancellation Test
Overall score 17.0 (9.3) 18.8 (11.6) 1.8 (14.1) 25.3 (25.0) 21.7 (8.4) −3.7 (22.6) −0.4 (−2.1, 1.3)
CANTAB pattern recognition memory
% Correct 61.5 (23.5) 67.3 (17.4) 5.8 (6.7) 56.6 (12.3) 57.0 (12.2) 0.4 (13.4) −0.9 (−1.9, 0.1)
Cats and Dogs switching condition
Time taken 58.8 (36.3) 47.0 (31.5) −11.8 (26.3) 40.5 (22.0) 44.0 (10.9) 3.5 (27.4) 0.05 (−1.3, 1.4)
Number of errors 4.1 (5.3) 7.0 (8.2) 2.9 (8.6) 11.0 (7.6) 7.8 (7.5) −3.3 (6.5) –a
Tower of London Test (revised for learning disabilities)
Total score 21.7 (8.5) 24.8 (13.6) 3.1 (11.1) 20.7 (8.0) 20.3 (11.7) −0.3 (18.4) −0.7 (−2.3, 0.86)
Cued Recall Test
Total score 34.1 (4.5) 28.7 (13.0) −5.4 (12.7) 21.2 (12.7) 12.8 (14.2) −8.3 (13.9) –a
Category Fluency Test
Number correct 12.1 (4.2) 9.2 (3.9) −2.9 (4.4) 8.0 (4.2) 8.2 (6.1) 0.2 (3.5) 0.3 (−1.1, 1.7)
Number repeated 0.7 (1.1) 1.0 (1.1) 0.3 (0.9) 2.6 (1.7) 1.6 (1.1) −1.0 (1.2) 0.5 (−0.2, 1.3)
Number of errors 0.3 (0.5) 0.1 (0.3) −0.2 (0.7) 0.0 (0.0) 0.2 (0.5) 0.2 (0.5) –a
Story Recall Test
Free recall 5.8 (3.7) 3.6 (3.3) −2.1 (3.2) 5.0 (6.3) 3.0 (4.2) −2.0 (3.7) −0.4 (−1.2, 0.4)
Cued recall 4.4 (2.7) 3.9 (3.0) −0.5 (2.9) 2.4 (4.3) 2.6 (3.7) 0.2 (2.3) −0.6 (−1.8, 0.7)
Effect size reported as estimated between-group difference, adjusted for baseline score and stratification variables, divided by baseline SD in whole population,
and reversed where necessary so that a positive effect size corresponds to a benefit for simvastatin group
aThese are logistic models with decline versus no decline as the response; therefore, no effect size is given
CANTAB Cambridge Neuropsychological Test Automated Battery, NADIID Neuropsychological Assessment of Dementia in Individuals with Intellectual Disabilities
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professionals might be beneficial prior to embarking
upon a full-scale RCT, or as an early component of it
[54]. Another option might be to consider alternative
trial designs, such as a patient preference trial design;
however, negative as well as positive considerations are
needed in such choices, for example, a patient prefer-
ence design may increase the size and cost of a trial
which is already likely to be costly.
Whilst several Down syndrome cohorts exist, to our
knowledge, this is currently the largest worldwide, at age 50
and over, to have reported detailed cognitive testing longi-
tudinally. Previous studies have used cross-sectional mea-
surements of memory, attention, and executive functioning
to investigate cognitive decline with ageing, but there are
no longitudinal reports with more than a handful of partici-
pants aged 50 and over. Hence, this study is a major step
forward in delineating the most useful cognitive test battery
to show change over a short 12-month period for this age
group. As expected, cognitive performance was more
sensitive than carer-reported adaptive functioning. It also
provides accurate, rather than proxy, information. This is
particularly important given the necessity in some cases of
different carers providing information at baseline and
follow-up (due to staff-turnover, which is unavoidable in
research studies with this population), who may have
different perceptions/depth of information regarding
the person they support. A limitation in interpreting
the findings is, however, the small sample size.
The results show that further study of Aβ42/Aβ40 as a
potential biomarker is indicated in a larger sample.
Recruiting 60 people to the study was not feasible.
Due to the Down syndrome population age distribution,
it would have been considerably easier to recruit a larger
number had we lowered the entry age to, e.g. 40 or 45,
but given the much lower dementia incidence rate at
these different ages, it would have required a much
longer follow-up time to demonstrate cognitive decline,
and hence would not have been affordable as a pilot
study. We excluded people who had already acquired
dementia, as whilst simvastatin might be beneficial for
them, we hypothesised it more likely to be effective in
the earlier stages of amyloid deposition.
The prevalence of Down syndrome has varied over
time due to increasing life expectancy [61], access to
treatments for congenital heart defects with improved
surgical techniques and post-operative care [62], increas-
ing maternal age at birth [61], and rates of termination
of pregnancy. There is now widespread availability of,
and improved and improving methods of antenatal
screening for Down syndrome which initially led to an
increase in terminated pregnancies [61, 63]; but there
are also changing public attitudes, with growing accept-
ance and integration of disabled people in society. There
is some evidence to suggest that the number of people
born with Down syndrome is now increasing [64]. A
recent study reported Down syndrome in 1.2 of 1000
pregnancies, of which 78.1 % were live births. Survival
rate at 1 year for live-births in 1995–1999 was 91.6 %,
and 85 % are estimated to survive to 10 years [65]. The
proportion of people with Down syndrome reduces in
older cohorts [66]. These factors interplay to affect
prevalence: in the UK, adult prevalence is estimated at 6
per 10,000 general population [53, 67], but will rise with
increasing longevity. At present, there are approximately
30,000 adults with Down syndrome in the UK, of whom
about 7500 are aged over 50. Hence, dementia is currently
an important healthcare issue, and this will increase to be
more important in the future in this growing population.
Strategies for prevention and treatment are, therefore,
urgently needed: this feasibility study is a very important
first step towards this.
Conclusions
Dementia is a highly disabling, progressive disorder cul-
minating in premature death. It has a negative impact on
the adult with dementia, their family and friends, leads to
increasing health and social care resources being required,
and has a major societal and economic cost. Hence,
preventative measures are urgently needed for adults with
Down syndrome, and it is crucially important that trials
with, and for, them are undertaken. If statins are effective,
there is a case for their routine prescription for all adults
with Down syndrome. Simvastatin is a very cheap interven-
tion, at £1.23 per 28 tablets (US$1.86; 1.67 €) according to
the British National Formulary.
A full-scale RCT of simvastatin for the primary preven-
tion of dementia in older adults with Down syndrome is
feasible, despite the numerous challenges it poses. This
pilot study has provided essential information to enable
the design and implementation of a full-scale RCT. It has
also highlighted considerable need for publicity and edu-
cation on the reasons for, and benefits of, conducting
RCTs with this population.
This study provides information that is also likely to
benefit other future clinical studies with this population. It
provides an excellent examples of Cooksey type II transla-
tional research (a recognised research gap), inter-sectoral
collaboration, novel case identification, and instrument
technology development.
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